Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)
Publication
, Conference
Nixon, AB; Halabi, S; Shterev, I; Starr, M; Brady, JC; Dutcher, JP; Hopkins, JO; Hurwitz, H; Small, EJ; Rini, BI; Febbo, PG; George, DJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2013
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2013
Volume
31
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Nixon, A. B., Halabi, S., Shterev, I., Starr, M., Brady, J. C., Dutcher, J. P., … George, D. J. (2013). Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 31). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Nixon, Andrew B., Susan Halabi, Ivo Shterev, Mark Starr, John C. Brady, Janice P. Dutcher, Judith O. Hopkins, et al. “Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
Nixon AB, Halabi S, Shterev I, Starr M, Brady JC, Dutcher JP, et al. Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.
Nixon, Andrew B., et al. “Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).” JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 15, AMER SOC CLINICAL ONCOLOGY, 2013.
Nixon AB, Halabi S, Shterev I, Starr M, Brady JC, Dutcher JP, Hopkins JO, Hurwitz H, Small EJ, Rini BI, Febbo PG, George DJ. Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2013
Volume
31
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences